克拉霉素增强耐药慢性粒细胞白血病患者酪氨酸激酶抑制剂的治疗效果。 - Suppr

Suppr

超能文献

Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.

作者信息

Carella Angelo Michele, Beltrami Germana, Pica Gianmatteo, Carella Andrea, Catania Gioacchino

出版信息

Leuk Lymphoma. 2012 Jul;53(7):1409-11. doi: 10.3109/10428194.2012.656105. Epub 2012 Feb 13.

DOI:10.3109/10428194.2012.656105

PMID:22233113

Abstract

摘要

相似文献

Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.克拉霉素增强耐药慢性粒细胞白血病患者酪氨酸激酶抑制剂的治疗效果。

Leuk Lymphoma. 2012 Jul;53(7):1409-11. doi: 10.3109/10428194.2012.656105. Epub 2012 Feb 13.

BCR-ABL mutant kinetics in CML patients treated with dasatinib.达沙替尼治疗的慢性粒细胞白血病患者中BCR-ABL突变动力学

Leuk Res. 2007 Jun;31(6):865-8. doi: 10.1016/j.leukres.2006.12.003. Epub 2007 Jan 8.

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.一名慢性髓性白血病进展为淋巴细胞母细胞危象的患者中导致对甲磺酸伊马替尼和达沙替尼均耐药的序贯突变

Leuk Res. 2008 Apr;32(4):673-4. doi: 10.1016/j.leukres.2007.08.008. Epub 2007 Sep 24.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.达沙替尼用于伊马替尼耐药的费城染色体阳性白血病。

N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.伏立诺他（辛二酰苯胺异羟肟酸）与达沙替尼（BMS-354825）联合治疗可增强达沙替尼对甲磺酸伊马替尼敏感或甲磺酸伊马替尼耐药的慢性粒细胞白血病细胞的活性。

Clin Cancer Res. 2006 Oct 1;12(19):5869-78. doi: 10.1158/1078-0432.CCR-06-0980.

Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.达沙替尼克服了两名慢性髓性白血病患者中 F359I 残基突变介导的伊马替尼耐药。

Acta Haematol. 2012;127(1):56-9. doi: 10.1159/000333092. Epub 2011 Nov 17.

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.F317L BCR-ABL1激酶结构域突变与一名接受达沙替尼治疗的慢性粒细胞白血病患者持续的主要分子反应相关。

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12.

Dasatinib in chronic myelogenous leukemia.达沙替尼治疗慢性粒细胞白血病

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4.

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。

Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.Polo-like 激酶 1（Plk1）作为慢性髓性白血病的一个新的药物靶点：用 Plk1 抑制剂 BI 2536 克服伊马替尼耐药性。

Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9.

引用本文的文献

Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.慢性髓性白血病的无治疗缓解：重新审视“W”问题。

Eur J Haematol. 2025 Sep;115(3):218-231. doi: 10.1111/ejh.70000. Epub 2025 Jun 23.

Autophagy and Cancer: Insights into Molecular Mechanisms and Therapeutic Approaches for Chronic Myeloid Leukemia.自噬与癌症：慢性髓性白血病分子机制及治疗方法的见解

Biomolecules. 2025 Feb 2;15(2):215. doi: 10.3390/biom15020215.

Repurposing Drugs in Small Animal Oncology.小动物肿瘤学中的药物再利用

Animals (Basel). 2022 Dec 29;13(1):139. doi: 10.3390/ani13010139.

Overcoming Therapy Resistance in Colon Cancer by Drug Repurposing.通过药物重新利用克服结肠癌的治疗耐药性

Cancers (Basel). 2022 Apr 23;14(9):2105. doi: 10.3390/cancers14092105.

Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases.新冠病毒感染后转移性肾细胞癌的自发消退：两例报告。

Curr Oncol. 2021 Sep 3;28(5):3403-3407. doi: 10.3390/curroncol28050294.

Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels.大环内酯类抗生素通过抑制hERG1钾通道调节自噬通量，从而发挥抗白血病作用。

Blood Cancer J. 2016 May 13;6(5):e423. doi: 10.1038/bcj.2016.32.

Drug repurposing in oncology--patient and health systems opportunities.肿瘤学中的药物再利用——患者和医疗体系的机遇。

Nat Rev Clin Oncol. 2015 Dec;12(12):732-42. doi: 10.1038/nrclinonc.2015.169. Epub 2015 Oct 20.

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.肿瘤学中药物的重新利用（ReDO）——克拉霉素作为一种抗癌药物。

Ecancermedicalscience. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513. eCollection 2015.

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.慢性髓性白血病中根除恶性克隆的替代方法：酪氨酸激酶抑制剂联合应用及其他。

Hematology Am Soc Hematol Educ Program. 2013;2013:189-200. doi: 10.1182/asheducation-2013.1.189.

Autophagy in blood cancers: biological role and therapeutic implications.血液癌症中的自噬：生物学作用和治疗意义。

Haematologica. 2013 Sep;98(9):1335-43. doi: 10.3324/haematol.2012.079061.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验